TY - JOUR
AR - ACO-2020-3-102
TI - Appearance of 4 Degree Rash While Treating Advanced Lung Cancer with Icotinib – Whether to Stop the Drug: A Case Report
AU - Li, Lv
AU - Lifeng , Jiang
AU - Wenhui , Zhang
AU - Xinyan , Lu
AU - Tingting , Li
AU - Jie, Lin
JO - Annals of Clinical Oncology
PY - 2020
DA - Mon 14, Dec 2020
SN - 2674-3248
DO - http://dx.doi.org/10.31487/j.ACO.2020.03.02
UR - https://www.sciencerepository.org/appearance-of-4-degree-rash-while-treating-advanced-lung-cancer_ACO-2020-3-102 
KW -  Lung cancer, icotinib, adverse reactions, rash
AB - Skin and skin adnexa toxicities are the most common side effects associated with epidermal growth factor
receptor tyrosine kinase inhibitors (EGFR-TKIs). Previous research showed that the rash appeared, and the
severity of EGFR-TKIs may be a marker of clinical benefit. In this context, we report a 75-year-old man
with advanced lung cancer who on receiving icotinib developed severe adverse reactions, 4 degree rash
(NCI-CTC AE version 4.0 common toxicity grading standards grade), and refused to stop taking the drug;
but with the anti-infection and symptomatic nursing, the patient recovered, the rash disappeared, and the
patient received a better prognosis. Thus, we would like to emphasize the importance of deciding whether
to stop the drug when patients developed adverse reactions of 3-4 degree rash.